TY  - JOUR
AU  - Božić, Bojana
AU  - Vidonja Uzelac, Teodora
AU  - Kezić, Aleksandra
AU  - Bajčetić, Milica
PY  - 2018
UR  - http://www.eurekaselect.com/153927/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3052
AB  - Historically, quinidine was the first medicine used in the therapy of heart arrhythmias. Studies in the early 20th century identified quinidine, a diastereomer of the antimalarial quinine, as the most potent of the antiarrhythmic substances extracted from the cinchona plant. Quinidine is used by the 1920s, as an antiarrhythmic agent to maintain sinus rhythm after the conversion from atrial flutter or atrial fibrillation and to prevent recurrence of ventricular tachycardia or ventricular fibrillation. Its value in chronic prophylaxis of relapse of ventricular arrhythmia was brought under suspicion after publishing of meta analysis that showed that the application of quinidine increases mortality. Due to numerous proofs of increased risk for the appearance of ventricular arrhythmia and sudden death, as well as a number of other adverse effects and drug interactions, quinidine was withdrawn from use and in the recent years has become unavailable in many countries. On the other hand, recent studies have demonstrated that quinidine is the only oral medication that has consistently shown efficacy in preventing arrhythmias and terminating storms due to recurrent ventricular fibrillation, in patients with Brugada syndrome, idiopathic ventricular fibrillation and early repolarization syndrome. Quinidine is also the only antiarrhythmic drug that normalized the QT interval in patients with the congenital short QT syndrome. The aim of this review is to provide good insight into pro and contra arguments for quinidine use in ventricular arrhythmias evidence based on recently published literature.
T2  - Mini Reviews in Medicinal Chemistry
T1  - The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.
IS  - 6
VL  - 18
DO  - 10.2174/1389557517666170707110450
SP  - 468
EP  - 475
ER  - 

@article{
author = "Božić, Bojana and Vidonja Uzelac, Teodora and Kezić, Aleksandra and Bajčetić, Milica",
year = "2018",
abstract = "Historically, quinidine was the first medicine used in the therapy of heart arrhythmias. Studies in the early 20th century identified quinidine, a diastereomer of the antimalarial quinine, as the most potent of the antiarrhythmic substances extracted from the cinchona plant. Quinidine is used by the 1920s, as an antiarrhythmic agent to maintain sinus rhythm after the conversion from atrial flutter or atrial fibrillation and to prevent recurrence of ventricular tachycardia or ventricular fibrillation. Its value in chronic prophylaxis of relapse of ventricular arrhythmia was brought under suspicion after publishing of meta analysis that showed that the application of quinidine increases mortality. Due to numerous proofs of increased risk for the appearance of ventricular arrhythmia and sudden death, as well as a number of other adverse effects and drug interactions, quinidine was withdrawn from use and in the recent years has become unavailable in many countries. On the other hand, recent studies have demonstrated that quinidine is the only oral medication that has consistently shown efficacy in preventing arrhythmias and terminating storms due to recurrent ventricular fibrillation, in patients with Brugada syndrome, idiopathic ventricular fibrillation and early repolarization syndrome. Quinidine is also the only antiarrhythmic drug that normalized the QT interval in patients with the congenital short QT syndrome. The aim of this review is to provide good insight into pro and contra arguments for quinidine use in ventricular arrhythmias evidence based on recently published literature.",
journal = "Mini Reviews in Medicinal Chemistry",
title = "The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.",
number = "6",
volume = "18",
doi = "10.2174/1389557517666170707110450",
pages = "468-475"
}

Božić, B., Vidonja Uzelac, T., Kezić, A.,& Bajčetić, M.. (2018). The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.. in Mini Reviews in Medicinal Chemistry, 18(6), 468-475.
https://doi.org/10.2174/1389557517666170707110450

Božić B, Vidonja Uzelac T, Kezić A, Bajčetić M. The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'.. in Mini Reviews in Medicinal Chemistry. 2018;18(6):468-475.
doi:10.2174/1389557517666170707110450 .

Božić, Bojana, Vidonja Uzelac, Teodora, Kezić, Aleksandra, Bajčetić, Milica, "The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias 'Quinidine'." in Mini Reviews in Medicinal Chemistry, 18, no. 6 (2018):468-475,
https://doi.org/10.2174/1389557517666170707110450 . .

TY  - JOUR
AU  - Bajčetić, Milica
AU  - Vidonja Uzelac, Teodora
PY  - 2012
PY  - 2012
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/344
AB  - This paper is focused on the most prominent problems of the contemporary pediatric pharmacotherapy: the lack of pediatrically designed and evaluated drugs, as well as the lack of pediatric formulations for children under 12 years of age. The availability of drugs that can be used in the treatment of children is significantly limited with the lack of pediatric formulations both for oral and parenteral use. Besides that, a majority of drugs that are used in the therapy of neonates and children's are not properly evaluated, so they are used off-label and unlicensed, which significantly influences efficacy and safety of a therapy. In addition, certain excipients that should be pharmacologically inactive can eventually cause severe adverse effects in neonates and infants. The dosing of drugs in formulations that can be used by children, based on results of pediatric clinical studies, is the utmost imperative of the contemporary pediatric pharmacotherapy.
AB  - Ovaj rad je fokusiran na najznačajnije probleme savremene farmakoterapije u pedijatriji: nedostatak pedijatrijski dizajniranih i evaluiranih lekova, kao i nedostatak pedijatrijskih formulacija za decu mlađu od 12 godina. Dostupnost lekova koji se mogu koristiti u terapiji dece značajno je ograničena nedostatkom pedijatrijskih formulacija kako za oralnu tako i za parenteralnu primenu. Osim toga, veliki broj lekova koji se svakodnevno koristi u terapiji novorođene dece nije propisno evaluiran i upotrebljava se najčešće mimo propisane licence, što značajno utiče na efikasnost i bezbednost terapije. Osim toga, pojedine pomoćne supstance, koje u principu treba da budu farmakološki neaktivna jedinjenja, mogu izazvati ozbiljne neželjene efekte kod novorođenčadi i odojčadi. Doziranje lekova u formulacijama koje mogu da koriste deca, zasnovano na rezultatima pedijatrijskih kliničkih studija, imperativ je savremene farmakoterapije dece.
T2  - Arhiv za farmaciju
T1  - Raspoloživost, efikasnost i kvalitet lekova u pedijatriji
T1  - Availability, quality and efficacy of drugs for use in pediatric patients
IS  - 4
VL  - 62
SP  - 279
EP  - 287
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_344
ER  - 

@article{
author = "Bajčetić, Milica and Vidonja Uzelac, Teodora",
year = "2012, 2012",
abstract = "This paper is focused on the most prominent problems of the contemporary pediatric pharmacotherapy: the lack of pediatrically designed and evaluated drugs, as well as the lack of pediatric formulations for children under 12 years of age. The availability of drugs that can be used in the treatment of children is significantly limited with the lack of pediatric formulations both for oral and parenteral use. Besides that, a majority of drugs that are used in the therapy of neonates and children's are not properly evaluated, so they are used off-label and unlicensed, which significantly influences efficacy and safety of a therapy. In addition, certain excipients that should be pharmacologically inactive can eventually cause severe adverse effects in neonates and infants. The dosing of drugs in formulations that can be used by children, based on results of pediatric clinical studies, is the utmost imperative of the contemporary pediatric pharmacotherapy., Ovaj rad je fokusiran na najznačajnije probleme savremene farmakoterapije u pedijatriji: nedostatak pedijatrijski dizajniranih i evaluiranih lekova, kao i nedostatak pedijatrijskih formulacija za decu mlađu od 12 godina. Dostupnost lekova koji se mogu koristiti u terapiji dece značajno je ograničena nedostatkom pedijatrijskih formulacija kako za oralnu tako i za parenteralnu primenu. Osim toga, veliki broj lekova koji se svakodnevno koristi u terapiji novorođene dece nije propisno evaluiran i upotrebljava se najčešće mimo propisane licence, što značajno utiče na efikasnost i bezbednost terapije. Osim toga, pojedine pomoćne supstance, koje u principu treba da budu farmakološki neaktivna jedinjenja, mogu izazvati ozbiljne neželjene efekte kod novorođenčadi i odojčadi. Doziranje lekova u formulacijama koje mogu da koriste deca, zasnovano na rezultatima pedijatrijskih kliničkih studija, imperativ je savremene farmakoterapije dece.",
journal = "Arhiv za farmaciju",
title = "Raspoloživost, efikasnost i kvalitet lekova u pedijatriji, Availability, quality and efficacy of drugs for use in pediatric patients",
number = "4",
volume = "62",
pages = "279-287",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_344"
}

Bajčetić, M.,& Vidonja Uzelac, T.. (2012). Raspoloživost, efikasnost i kvalitet lekova u pedijatriji. in Arhiv za farmaciju, 62(4), 279-287.
https://hdl.handle.net/21.15107/rcub_ibiss_344

Bajčetić M, Vidonja Uzelac T. Raspoloživost, efikasnost i kvalitet lekova u pedijatriji. in Arhiv za farmaciju. 2012;62(4):279-287.
https://hdl.handle.net/21.15107/rcub_ibiss_344 .

Bajčetić, Milica, Vidonja Uzelac, Teodora, "Raspoloživost, efikasnost i kvalitet lekova u pedijatriji" in Arhiv za farmaciju, 62, no. 4 (2012):279-287,
https://hdl.handle.net/21.15107/rcub_ibiss_344 .

TY  - JOUR
AU  - Ilić, Katarina
AU  - Jelenković, Ankica V.
AU  - Bajčetić, Milica
AU  - Jovanović, Tomislav
PY  - 2006
PY  - 2006
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/245
AB  - The effect of L-thyroxine on the dynamics of body mass changes was investigated in the adult guinea pigs. The acute administration of thyroxine had a strong effect on their body mass. The animals receiving thyroxine had a statistically significant less increase in body mass comparing to the euthyreoid animals. However, this effect of thyroxine appears after a latent period required for a depletion of the present energetic depots and overcoming the energetic compensatory mechanisms.
AB  - Proučavan je efekat L-tiroksina na dinamičke promene telesne mase kod odraslih zamorčića. Akutno davanje tiroksina je imalo izražen efekat na telesnu masu zamorčića. Životinje koje su primale tiroksin imale su statistički značajno manji porast telesne mase u poređenju sa eutireoidnim životinjama. Međutim, ovaj efekat se ispoljavao posle latentnog perioda potrebnog da se istroše postojeće energetske rezerve i da se nadvladaju energetski kompenzatorni mehanizmi.
T2  - Acta biologica serbica - serija C: Acta physiologica et pharmacologica serbica
T1  - Dinamika promena telesne mase zamorčića tretiranih L-tiroksinom
T1  - The dynamics of body mass changes in the guinea pigs treated by L - thyroxine
IS  - 2
VL  - 42
SP  - 115
EP  - 122
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_245
ER  - 

@article{
author = "Ilić, Katarina and Jelenković, Ankica V. and Bajčetić, Milica and Jovanović, Tomislav",
year = "2006, 2006",
abstract = "The effect of L-thyroxine on the dynamics of body mass changes was investigated in the adult guinea pigs. The acute administration of thyroxine had a strong effect on their body mass. The animals receiving thyroxine had a statistically significant less increase in body mass comparing to the euthyreoid animals. However, this effect of thyroxine appears after a latent period required for a depletion of the present energetic depots and overcoming the energetic compensatory mechanisms., Proučavan je efekat L-tiroksina na dinamičke promene telesne mase kod odraslih zamorčića. Akutno davanje tiroksina je imalo izražen efekat na telesnu masu zamorčića. Životinje koje su primale tiroksin imale su statistički značajno manji porast telesne mase u poređenju sa eutireoidnim životinjama. Međutim, ovaj efekat se ispoljavao posle latentnog perioda potrebnog da se istroše postojeće energetske rezerve i da se nadvladaju energetski kompenzatorni mehanizmi.",
journal = "Acta biologica serbica - serija C: Acta physiologica et pharmacologica serbica",
title = "Dinamika promena telesne mase zamorčića tretiranih L-tiroksinom, The dynamics of body mass changes in the guinea pigs treated by L - thyroxine",
number = "2",
volume = "42",
pages = "115-122",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_245"
}

Ilić, K., Jelenković, A. V., Bajčetić, M.,& Jovanović, T.. (2006). Dinamika promena telesne mase zamorčića tretiranih L-tiroksinom. in Acta biologica serbica - serija C: Acta physiologica et pharmacologica serbica, 42(2), 115-122.
https://hdl.handle.net/21.15107/rcub_ibiss_245

Ilić K, Jelenković AV, Bajčetić M, Jovanović T. Dinamika promena telesne mase zamorčića tretiranih L-tiroksinom. in Acta biologica serbica - serija C: Acta physiologica et pharmacologica serbica. 2006;42(2):115-122.
https://hdl.handle.net/21.15107/rcub_ibiss_245 .

Ilić, Katarina, Jelenković, Ankica V., Bajčetić, Milica, Jovanović, Tomislav, "Dinamika promena telesne mase zamorčića tretiranih L-tiroksinom" in Acta biologica serbica - serija C: Acta physiologica et pharmacologica serbica, 42, no. 2 (2006):115-122,
https://hdl.handle.net/21.15107/rcub_ibiss_245 .